See the Future Clearly

Beautiful View

Equipped with all the advantages of the proven Allegretto Wave® technology, the Allegretto Wave® Eye-Q is one step further towards optimum laser vision correction. Designed to work in perfect harmony with other diagnostic and surgical products from the WaveLight range, the Eye-Q provides both physician and patient with a higher level of safety and reliability.

Allegretto Wave Eye-Q System

Speed and Spot size
–400 Hz ablation rate
–Approx. 2 seconds (1.8) per diopter ablation
–0.95 mm Gaussian laser beam

Why speed matters
• Reduces stromal dehydration
• Reduces exposure to temperature and humidity factors
• Improves patient fixation time
• Improves patient comfort throughout

The significance of a Gaussian beam profile

The treated surface of the patient's cornea is reshaped smoothly with a Gaussian beam like the Allegretto. Flat-top beam lasers leave a rough, notched surface on the cornea.

Ablation Profiles-Gaussian Beam vs. Flat-top Beam

Its state-of-the-art technology provides superior results with WaveLight’s Wavefront Optimized™ approach. Allegretto Wave® lasers are the only systems to use Wavefront Optimized ablation profiles as part of their treatments. The use of Wavefront Optimized ablation prevents or reduces the induction of spherical aberrations. This results in better night vision and less sensitivity to glare. The natural shape of the human cornea is aspheric. This means that all light rays meet in one sharp focus point. Therefore the Allegretto Wave laser systems perform an ablation with the objective of maintaining a natural postoperative corneal shape, thereby preserving the cornea’s asphercity. Every treatment is customized to the patient’s individual refraction and corneal curvature.

Ablation Profiles

The Allegretto Wave® Eye-Q operates at the high speed of 400 pulses per second. Each ultra-thin laser pulse is used to sculpt the corneal surface with the utmost precision. In order to further enhance the safety and precision of the treatment, Perfect Pulse Technology® uses advanced high-speed eye tracking to follow the eye’s fastest movements and to ensure an accurate placement of each laser pulse on the cornea.

Using a fine laser beam at such high speed, the Allegretto Wave® Eye-Q relies on its 400 Hz synchronous, video-based, active eye tracker to follow even the fastest eye movements with a response time of less than 6 ms. As a pupil-based system, it tracks pupils between 1.8 mm and 8 mm, and the automatic centering mode ensures perfectly centered ablations. The closed-loop tracking mode reconfirms the eye‘s location again before a pulse is placed on the cornea, to ensure that every pulse goes into the desired location. To monitor the patient‘s eye, the active eye tracker utilizes three infrared light sources. Being infrared, the illumination sources cannot cause thermal heating. The illumination sources are independent, meaning that the tracker will continue to work even if one of the pods is covered by the surgeon‘s hand or a sterile drape, and the gooseneck shape of the illumination pods prevents backscattering of surgery.

Finding the eye‘s right treatment position and avoiding displacements caused by cyclotorsion is one of the most important factors in obtaining an excellent refractive outcome. The Allegretto Wave® Eye-Q‘s integrated cross line projector provides the surgeon an exact alignment of the eye’s position. The target diode which generates a red light cross hair on the patient‘s face, illustrating the correct position in coordination with the manual marks. With the Allegretto Wave® Eye-Q, a surgeon can also treat difficult cases or patients with a high cyclotorsion value up to 15% and still produce excellent results. This was demonstrated by the FDA clinical trials having a cornering predictability from ± 0.5 D.

The Allegretto Wave® Eye-Q is approved to treat myopia up to –12 diopters with astigmatism of up to –6 diopters and hyperopia up to +6 diopters with astigmatism of up to +5 diopters, not exceeding a mean spherical equivalent of +6 diopters. For more information about the benefits and risks associated with this product, please visit www.fda.gov, www.wavelight.com/eyes, www.allegrettowave.com.

Disclaimer for Myopia: a. Approval of the premarket approval application is for the WaveLight Allegretto Wave® Eye-Q Excimer Laser System to perform LASIK treatments in patients 18 years of age or older for the reduction or elimination of myopic refractive errors up to –12.0 diopters (D) of sphere with and without astigmatic refractive errors up to –6.0 D, and in patients with documented evidence of a stable manifest refraction defined as less than or equal to 0.50 D of preoperative spherical equivalent shift over one year prior to surgery. b. LASIK is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), and other refractive surgeries. c. Approval of the application is based on clinical trials in the United States with 901 eyes treated, of which 813 of 866 eligible eyes were followed for 12 months. Accountability at 3 months was 93.8%, at 6 months was 91.9%, and at 12 months was 93.9%. d. The studies found that of the 844 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at the 3-month stability time point, 98.0% were corrected to 20/40 or better, and 84.4% were corrected to 20/20 or better without spectacles or contact lenses. e. The clinical trials showed that the following subjective patient adverse events were reported as “moderate to severe” at a level at least 1% higher than baseline of the subjects at 3 months post-treatment: visual fluctuations (12.8% at baseline versus 28.6% at 3 months). f. Long-term risks of LASIK for myopia with and without astigmatism beyond 12 months have not been studied. g. Note that the complete name for this ophthalmic laser is “WaveLight Allegretto Wave® Eye-Q Excimer Laser System for laser assisted insitu keratomileusis (LASIK) treatments of myopic refractive errors up to –12.0 diopters (D) of sphere with and without astigmatic refractive errors up to –6.0D at the spectacle plane“.

Disclaimer for Hyperopia: a. Approval of the premarket approval application is for the WaveLight Allegretto Wave® Eye-Q Excimer Laser System to perform LASIK treatments in patients 18 years of age or older for the reduction or elimination of hyperopic refractive errors up to +6.0 diopters (D) of sphere with and without astigmatic refractive errors up to 5.0 D at the spectacle plane, with a maximum manifest refraction spherical equivalent (MRSE) of +6.0 D; and in patients with documented evidence of a stable manifest refraction defined as less than or equal to 0.50 D of preoperative spherical equivalent shift over one year prior to surgery, exclusive of changes due to unmasking latent hyperopia.
b. LASIK is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), and other refractive surgeries.
c. Approval of the application is based on clinical trials in the United States with 290 eyes treated, of which 100 of 290 eligible eyes were followed for 12 months. Accountability at 3 months was 95.2%, at 6 months was 93.9%, and at 12 months was 69.9%.
d. The studies found that of the 212 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at the 6-month stability time point, 95.3% were corrected to 20/40 or better, and 67.5 % were corrected to 20/20 or better without spectacles or contact lenses.
e. The study showed that the following subjective patient adverse events were reported as “much worse” by at least 1% of the subjects (in order of increasing frequency) at 6 months post final treatment: glare from bright lights (3.0%); night-driving glare (4.2%); light sensitivity (4.9%); visual fluctuations (6.1%); and halos (6.4%).
f. Long term risks of LASIK for hyperopia with and without astigmatism beyond 12 months have not been studied.
g. Note that the complete name for this ophthalmic laser is “WaveLight Allegretto Wave® Eye-Q Excimer Laser System for laser assisted insitu keratomileusis (LASIK) treatments of hyperopic refractive errors up to +6.0 diopters (D) of sphere with and without astigmatic refractive errors up to 5.0 D with a maximum manifest refraction spherical equivalent (MRSE) of +6.0 D“.